About: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 20 March 2014

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2014 (uk) article scientifique publié en 2014 (fr) scientific article published on 20 March 2014 (en) artículu científicu espublizáu en marzu de 2014 (ast) im März 2014 veröffentlicher wissenschaftlicher Artikel (de)
publication date	wds:Q57579888-31367641-F7A4-4AD5-A117-DC94FC084D1C
publication date	2014-03-20 00:00:00Z (xsd:dateTime)
cites work	wds:Q57579888-021CD92C-25BB-4A6B-A8F0-76146C11FAD6 wds:Q57579888-07425720-FCC8-4432-A05C-0F19611EF646 wds:Q57579888-100FFBB8-9566-4A86-B0B4-74D26AA0DFC2 wds:Q57579888-3C9F0873-99DD-4D66-BFC0-1E1765CFECD2 wds:Q57579888-445D916D-164A-42AF-84E1-0A94BA4CCC16 wds:Q57579888-63FFDB6B-13D0-4861-8CFF-F677374BFD3A wds:Q57579888-64F96939-7E2E-4320-B419-86EEDBDC2AD0 wds:Q57579888-728D861D-3D90-402A-9BB9-9C99800950CB wds:Q57579888-74B1BAB3-03BB-4CCA-A6D5-19B7620E426D wds:Q57579888-8194222F-C939-4062-A42D-EB20FEEA022A wds:Q57579888-8388CCE0-6C94-450F-A767-7E979F7D32AD wds:Q57579888-8EB071CD-7421-4953-BC6B-7E83E3F12237 wds:Q57579888-996EB2D1-ECE2-47D1-B9EB-5273E1076C1C wds:Q57579888-9A62724F-DA5B-4B98-BE30-833F18CBCF69 wds:Q57579888-9BD749C5-CE9A-43E8-B828-94613478754F wds:Q57579888-C3C36380-5C40-4543-8DD1-2337463B2F12 wds:Q57579888-FF27D07D-EE1A-44DE-9313-BD4151BA4D7F
cites work	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer Pathological complete response and accelerated drug approval in early breast cancer Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall Adjuvant trastuzumab in HER2-positive breast cancer Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?
author name string	wds:Q57579888-137ABA66-5D71-415E-8071-9B9F58180607 wds:Q57579888-2DB37F12-7E48-4BCA-9BD1-B06088039B28 wds:Q57579888-2DF16761-B3A9-4FCF-AF0C-8B6AB012A50F wds:Q57579888-36D2219C-6C4D-4CDF-8F61-A03841BAC7CE wds:Q57579888-53D98D88-281B-4E8A-B0F8-A8824F9D5168 wds:Q57579888-573D9DD2-647C-461C-91A4-70CF253AEC59 wds:Q57579888-58152A79-B475-4352-BFD1-087F775C9836 wds:Q57579888-582FD938-D2A2-4967-995D-DAAA1E16459B wds:Q57579888-63D44E41-3527-43EF-98AE-6B3D9B7BDA0C wds:Q57579888-6E4735F4-8844-4F14-9E39-5E1E32F8FAD1 wds:Q57579888-7F0FC85A-EE0C-4BDF-95A4-330F7BD7713C wds:Q57579888-A2379004-908A-45C3-B6D6-6CBD6304B2A5 wds:Q57579888-A29958B7-640F-4BB0-8825-FA00427498C5 wds:Q57579888-A5C71EEA-472D-4944-AB6A-C1868156FC61 wds:Q57579888-D4CB3356-813B-4C8A-8376-4C744FBF3F8B wds:Q57579888-DD1972AA-40F0-4D92-B685-3CED08019AFA
author name string	Pinuccia Valagussa Jose Baselga Wolfgang Eiermann Mikhail Lichinitser Sergei Tjulandin Miguel Angel Climent Mauro Mansutti Dominik Heinzmann Jutta Steinseifer Domenico Magazzù Milvia Zambetti Federico Vazquez Alla Bozhok Angela Moliterni Belen Ojeda Mikhail J Byakhov
rdfs:label	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (en) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (nl)
skos:prefLabel	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (en) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (nl)
name	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (en) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (nl)
author	wds:Q57579888-5B6C8A2C-32E6-467D-A8C9-FB68FD216163 wds:Q57579888-765945F8-01DE-4C65-B5F0-D08B9255EBA6 wds:Q57579888-E6E6C9DA-47EF-418E-9D86-E73F8C9AB701 wds:Q57579888-F136ABA7-B6F1-4CCC-905B-E857FDE34164
author	Vladimir Semiglazov Luca Gianni Ana Lluch Eva M Ciruelos
title	wds:Q57579888-FC4A7B38-89BA-4214-8C63-DD658F7F9EE2
title	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (en)
page(s)	wds:Q57579888-437036E1-668C-46AE-AC6E-3C416ACACCC5
page(s)	640-647
instance of	wds:Q57579888-9BA69EC3-0874-451C-AA07-08E8EC9B6D09
instance of	scholarly article
main subject	wds:Q57579888-3C45B456-580E-4C10-8993-0ECF8AFD53D0 wds:Q57579888-F44BBCCA-16D5-4535-A5FB-9C2C8FF3C373 wds:Q57579888-FB87C794-9F36-4DC5-A8FD-67B42F63E0C4
main subject	trastuzumab breast cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software